Insights from Dr. Ravi Chauhan, MD, FACS
Bladder cancer remains one of the most challenging urologic cancers to diagnose and manage, particularly when it comes to high-risk non-muscle invasive bladder cancer (NMIBC). In a recent discussion, Dr. Ravi Chauhan, a board-certified urologist and fellowship-trained uro-oncology specialist at the Conrad Pearson Clinic, shared his perspective on how advances in diagnostics and treatment are reshaping care for patients with bladder cancer. In this video, Dr. Chauhan steps through the newer treatment options for bladder cancer.
A Personal Commitment to Patient-Centered Care
Born and raised in Memphis, Tennessee, Dr. Chauhan’s journey into medicine was inspired by watching his father practice medicine and witnessing the profound impact physicians can have on patients and families. That experience helped shape a philosophy centered on compassion, respect, and treating every patient as if they were a member of his own family.
Today, Dr. Chauhan is recognized as a leader in the treatment of advanced kidney and bladder cancers, bringing both clinical expertise and a patient-focused approach to complex cancer care.
The Challenge of Detecting High-Risk Non-Muscle Invasive Bladder Cancer
One of the central topics of discussion was the difficulty of identifying carcinoma in situ (CIS), a particularly aggressive form of bladder cancer that can be difficult to detect using traditional diagnostic methods.
Unlike larger tumors that may be visible during routine cystoscopy, CIS often appears as flat, subtle lesions that can easily be overlooked. Missing or under-recognizing these lesions can significantly impact treatment decisions and ultimately affect patient outcomes.
For patients, early and accurate diagnosis is critical because CIS carries a higher risk of progression to muscle-invasive disease if left untreated.
Why Pathology Collaboration Matters
As bladder cancer management becomes increasingly sophisticated, collaboration between urologists and pathologists is more important than ever.
Dr. Chauhan emphasizes the importance of:
- Accurate tissue sampling
- Detailed pathological evaluation
- Consistent communication between specialists
- Timely interpretation of diagnostic findings
This multidisciplinary approach helps ensure that patients receive the most appropriate treatment based on the true extent of their disease.
Advances in pathology and diagnostic technologies are helping clinicians better identify high-risk disease earlier, allowing for more personalized treatment planning.
The Evolution of Precision Bladder Cancer Management
The field of bladder cancer care is rapidly moving toward precision medicine. Rather than relying solely on traditional clinical findings, physicians increasingly have access to:
- Enhanced diagnostic imaging
- Molecular testing
- Improved risk stratification tools
- Advanced surveillance technologies
These innovations help physicians tailor treatment strategies to individual patients, potentially improving outcomes while minimizing unnecessary interventions.
For community urologists, keeping pace with these evolving standards of care requires ongoing education and collaboration with specialists who focus on uro-oncology.
Exploring Bladder-Sparing Treatment Options
Historically, patients with high-risk BCG-unresponsive NMIBC often faced a difficult choice: undergo radical cystectomy (bladder removal) or accept the risk of disease progression.
Today, newer bladder-preserving therapies are expanding treatment options for select patients.
One notable advancement discussed was Adstiladrin® (nadofaragene firadenovec-vncg), an intravesical gene therapy approved for adults with high-risk BCG-unresponsive NMIBC with CIS, with or without papillary tumors.
This treatment represents an important development in bladder cancer care because it offers eligible patients a bladder-sparing option when traditional BCG therapy is no longer effective.
Understanding the Risks and Considerations
While bladder-preserving approaches are exciting, careful patient selection remains essential.
Experts emphasize that delaying cystectomy in patients with BCG-unresponsive CIS can increase the risk of developing muscle-invasive or metastatic bladder cancer. For patients who do not achieve a complete response after treatment or who experience recurrence, cystectomy may still be the most appropriate option.
Treatment decisions should always be individualized and made through shared discussions between patients and their healthcare team.
Looking Ahead
The future of bladder cancer care is being shaped by earlier detection, more precise diagnostics, and expanding treatment options.
As technologies continue to improve and collaboration between specialists deepens, patients with high-risk NMIBC may benefit from more personalized treatment pathways that balance cancer control with quality of life.
For physicians like Dr. Ravi Chauhan, the goal remains clear: identify disease earlier, treat it more effectively, and provide patients with the information and options they need to make informed decisions about their care.
